Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04230109 · ClinicalTrials.gov registry record · Phase 2
Sacituzumab Govitecan In TNBC
A Phase 2 study of Triple Negative Breast Cancer and HER2-Negative Breast Cancer, sponsored by Massachusetts General Hospital.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 260
- Enrollment target
- 5
- Study locations
NCT04230109 is a Phase 2 study of Triple Negative Breast Cancer and HER2-Negative Breast Cancer that is actively recruiting participants, run by Massachusetts General Hospital. The registered enrollment target is 260 participants, roughly in line with the 244-participant average among 118 other Triple Negative Breast Cancer trials with a reported enrollment target. The trial reports 5 study locations across 1 state.
The verdict
NCT04230109, a Phase 2 study of Triple Negative Breast Cancer and HER2-Negative Breast Cancer, is actively recruiting participants, sponsored by Massachusetts General Hospital.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 260 participants
- Enrollment target
- 5
- Study locations
Study Summary
This research study is studying to evaluate sacituzumab govitecan for individuals with localized triple negative breast cancer (TNBC) The names of the study drugs involved in this study is: * Sacituzumab govitecan (SG) * Pembrolizumab (combination therapy with SG)
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG Sacituzumab Govitecan
Study Locations (5)
Massachusetts
- Beth Israel Deaconess Medical Center - Boston
- Dana Farber Cancer Institute - Boston
- Massachusetts General Hospital - Boston
- Massachusetts General Hospital - North Shore Cancer Center - Danvers
- Massachusetts General Hospital at Newton-Wellesley Hospital - Newton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 260 participants |
| Start Date | 2020-07-14 |
| Est. Completion | 2029-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04230109
The ClinicalTrials.gov registry entry for NCT04230109 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 260 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 244-participant average among 118 other Triple Negative Breast Cancer trials with a reported enrollment target. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Triple Negative Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT04230109 reports 5 study locations spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT04230109 about?
NCT04230109 is a clinical study titled "Sacituzumab Govitecan In TNBC". This research study is studying to evaluate sacituzumab govitecan for individuals with localized triple negative breast cancer (TNBC) The names of the study drugs involved in this study is: * Sacituzumab govitecan (SG) * Pembrolizumab (combination therapy with SG)
What is the current status of trial NCT04230109?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 260 participants. The study started on 2020-07-14. Estimated completion is 2029-10.
What conditions does trial NCT04230109 study?
This clinical trial studies the following conditions: Triple Negative Breast Cancer, HER2-Negative Breast Cancer, Invasive Breast Cancer, ER-negative Breast Cancer, PR-Negative Breast Cancer.
What interventions are being tested in trial NCT04230109?
The interventions under investigation include: Pembrolizumab (DRUG), Sacituzumab Govitecan (DRUG).
Who is sponsoring clinical trial NCT04230109?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04230109 being conducted?
This trial has 5 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Triple Negative Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Anthracycline-Free Neoadjuvant Chemoimmunotherapy for Triple Negative Breast Cancer Patients
RECRUITING · Phase 2
-
Open-label, Single Center, Single-arm, Phase 2 Study of Neoadjuvant Pembrolizumab in Combination With Carboplatin and Paclitaxel in Patients With Stage 1 cT1b-T1cN0M0 Triple Negative Breast Cancer
RECRUITING · Phase 2
-
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
RECRUITING · Phase 2
-
Genomically Guided Radiation Therapy in the Management of Triple Negative Breast Cancer
RECRUITING · Phase 2
-
Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer
RECRUITING · Phase 2
-
A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer
RECRUITING · Phase 2
Explore more on PlainTrial
Triple Negative Breast Cancer
All registered trials for this condition
HER2-Negative Breast Cancer
All registered trials for this condition
Massachusetts
All trials with a study site in Massachusetts
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.